Publication | Closed Access

A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC)

UrologyOpen-label Phase 2Genitourinary CancerMedicinePharmacologyAnti-cancer AgentCxcr4 Inhibitor Ly2510924Cancer TreatmentOncologyMolecular Oncology